All Stories

  1. A semi-automated method for unbiased alveolar morphometry: Validation in a bronchopulmonary dysplasia model
  2. SARS-CoV-2 Infections and Impact of the COVID-19 Pandemic in Pregnancy and Breastfeeding: Results from an Observational Study in Primary Care in Belgium
  3. Treprostinil Attains Clinically Therapeutic Concentrations in Neonates with Pulmonary Hypertension on Extracorporeal Membrane Oxygenation Support
  4. Covariates of amikacin disposition in a large pediatric oncology cohort
  5. Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport
  6. Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11‐Year‐Old Children Born Preterm or At Term
  7. Renal Precision Medicine in Neonates and Acute Kidney Injury: How to Convert a Cloud of Creatinine Observations to Support Clinical Decisions
  8. Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
  9. The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
  10. The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study
  11. Acute Maternal Fasting or Fluid Abstention Does Not Significantly Affect the Macronutrient Composition of Human Milk: Clinical and Clinical Research Relevance
  12. Target Drug Exposure Attainment in Children: How to Get from Better to Best
  13. A core outcome set for neonatal opioid withdrawal
  14. Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review
  15. Pregnancy related pharmacokinetics and antimicrobial prophylaxis during fetal surgery, cefazolin and clindamycin as examples
  16. A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates
  17. Improved pathogen detection in neonatal sepsis to boost antibiotic stewardship
  18. The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties
  19. Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus
  20. Characterization of esophageal motility and esophagogastric junction in preterm infants with bronchopulmonary dysplasia
  21. Maternal Fasting or Fluid Abstention Does Not Significantly Affect the Macronutrient Composition of Human Milk: Clinical and Clinical Research Relevance
  22. Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials
  23. Glomerular Filtration Rate in Former Extreme Low Birth Weight Infants over the Full Pediatric Age Range: A Pooled Analysis
  24. Maturation of Esophageal Motility and Esophagogastric Junction in Preterm Infants
  25. A Critical Review on the Relevance of Paracetamol for Procedural Pain Management in Neonates
  26. “How can a drug to treat claudication in adults save preterm newborns?”
  27. A core outcome set for neonatal abstinence syndrome
  28. Acetaminophen Use in Pregnant Women and Their Neonates: Safe or Unsafe till Proven Otherwise?
  29. Arabic-speaking pregnant women with a migration background: A vulnerable target group for prenatal counseling on medicines
  30. Preterm birth impairs postnatal lung development in the neonatal rabbit model
  31. Integration of Placental Transfer in a Fetal–Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus
  32. Anatomical and physiological alterations of pregnancy
  33. Effect of esophageal length on high‐resolution manometry metrics: Extension to the neonatal population
  34. Glomerular Filtration Rate in Former Extreme Low Birth Weight Infants over the Full Pediatric Age Range: A Pooled Analysis
  35. Growth patterns and body composition in former extremely low birth weight (ELBW) neonates until adulthood: a systematic review
  36. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology
  37. Nonlinear Transfer Entropy to Assess the Neurovascular Coupling in Premature Neonates
  38. Pediatric Pharmacotherapy
  39. Perinatal pharmacology and safety profiles
  40. Special challenges in paediatric recruitment
  41. Introduction
  42. Simvastatin attenuates lung functional and vascular effects of hyperoxia in preterm rabbits
  43. Community pharmacists’ attitudes, barriers, knowledge and counseling practice with regard to preconception, pregnancy and lactation
  44. Intralesional steroid injections to prevent refractory strictures in patients with oesophageal atresia: study protocol for an international, multicentre randomised controlled trial (STEPS-EA trial)
  45. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia
  46. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants
  47. The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia
  48. A sensitive liquid chromatography method for analysis of propofol in small volumes of neonatal blood
  49. Development of a neonatal adverse event severity scale through a Delphi consensus approach
  50. Medical devices that look like medicines: safety and regulatory concerns for children in Europe.
  51. Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge
  52. Ontogeny of Phase I Metabolism of Drugs
  53. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle
  54. Propofol Formulation Affects Myocardial Function in Newborn Infants
  55. A manual propofol infusion regimen for neonates and infants
  56. Developmental neurobiology as a guide for pharmacological management of pain in neonates
  57. Health products’ and substance use among pregnant women visiting a tertiary hospital in Belgium: A cross‐sectional study
  58. Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women
  59. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation
  60. Prevalence and characteristics of pregnancy‐ and lactation‐related calls to the National Poison Centre in Belgium: A retrospective analysis of calls from 2012 to 2017
  61. Characterization of Esophageal Motility in Infants With Congenital Diaphragmatic Hernia Using High-resolution Manometry
  62. Monitoring of Brain Hemodynamics Coupling in Neonates using Updated Tensor Decompositions
  63. RAIN study: a protocol for a randomised controlled trial evaluating efficacy, safety and cost-effectiveness of intravenous-to-oral antibiotic switch therapy in neonates with a probable bacterial infection
  64. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (pha...
  65. Oral antibiotics for neonatal infections: a systematic review and meta-analysis
  66. Intravenous or Oral Acetaminophen for Analgesia After Cesarean Section: Exposure Drives Pain Relief
  67. Phenobarbital Increases Midazolam Clearance in Neonates Treated with Hypothermia: Do We Really Need to Know?
  68. Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen
  69. Clinical Pharmacokinetic Studies in Pregnant Women and the Relevance of Pharmacometric Tools
  70. Perinatal Clinical Pharmacology: Optimizing Pharmacotherapy for Pregnant Women, Their Fetuses and Infants
  71. Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates
  72. Erratum. Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother With KCNJ11-Related Neonatal Diabetes. Diabetes Care 2014;37:3333–3335
  73. O13 Improved early vancomycin exposure in neonates using a population pharmacokinetic model-based vancomycin dosing regimen
  74. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants
  75. Actual body weight-based vancomycin dosing in neonates
  76. Local pulmonary drug delivery in the preterm rabbit: feasibility and efficacy of daily intratracheal injections
  77. Morphine treatment for neonatal abstinence syndrome: huge dosing variability underscores the need for a better clinical study design
  78. Should we treat every infant with a probiotic?
  79. Perspectives in Neonatal Pharmacology: Drug Discovery, Knowledge Integration and Structured Prioritization
  80. Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates
  81. Beliefs about medicines and information needs among pregnant women visiting a tertiary hospital in Belgium
  82. Research on medication use in the neonatal intensive care unit
  83. Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools
  84. Rapidly maturing fentanyl clearance in preterm neonates
  85. Antenatal therapy with sildenafil: don't throw the baby out with the bathwater
  86. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children
  87. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
  88. Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
  89. Extremely Low Birth Weight Predisposes to Impaired Renal Health: A Pooled Analysis
  90. Narcotic-Sparing Approaches and the Shift Toward Paracetamol in Neonatal Intensive Care
  91. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute
  92. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model
  93. Developmental Pharmacology – Special Issues During Childhood and Adolescence
  94. Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability.
  95. Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans
  96. Maternal paracetamol intake and fetal ductus arteriosus constriction or closure: a case series analysis
  97. The use of PBPK modeling across the pediatric age range using propofol as a case
  98. (Preprint)
  99. (Preprint)
  100. Development of CliniPup®, a serious game for health aimed at reducing perioperative anxiety and pain in children (Preprint)
  101. CliniPup®, a web-based serious game for health to reduce perioperative anxiety and pain in children: a Pilot Study (Preprint)
  102. A4068 RISK OF HYPERTENSION AND BIRTH WEIGHT
  103. A0356 Conventional and ambulatory blood pressure as predictors of diastolic left ventricular function in a Flemish population
  104. Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I/IIb placenta transfer and safety study
  105. Developmental Changes in Pharmacokinetics and Pharmacodynamics
  106. Analgesics and Sedatives in Critically Ill Newborns and Infants: The Impact on Long-Term Neurodevelopment
  107. Rational Use of Medicines in Neonates: Current Observations, Areas for Research and Perspectives
  108. Cerebral autoregulation and activity after propofol for endotracheal intubation in preterm neonates
  109. Adaptive governance good practice: Show me the evidence!
  110. Community pharmacists’ questions related to pregnancy, lactation and preconception: An exploratory study in Belgium
  111. Medicines’ prescribing and dispensing during pregnancy: A retrospective analysis of Belgian hospital medical records and outpatient pharmacy data
  112. Using Graph Theory to Assess the Interaction between Cerebral Function, Brain Hemodynamics, and Systemic Variables in Premature Infants
  113. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered
  114. Pregnancy-related counselling in Belgian community pharmacies: A "mystery shopping" experience
  115. Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns
  116. Neonatal factors predictive for respiratory and gastro-intestinal morbidity after esophageal atresia repair
  117. Acetaminophen in the Neonatal Intensive Care Unit: Shotgun Approach or Silver Bullet
  118. Paracetamol in Older People: Towards Evidence-Based Dosing?
  119. Paracetamol/Acetaminophen During Pregnancy Induces Prenatal Ductus Arteriosus Closure
  120. Earlier achievement of full enteral feeding in extremely low birth weight neonates is not associated with growth improvement in the first 2 years of life
  121. Factors impacting unbound vancomycin concentrations in neonates and young infants
  122. Neonates are not just little children and need more finesse in dosing of antibiotics
  123. How often do we perform painful and stressful procedures in the paediatric intensive care unit? A prospective observational study
  124. In Vitro Adsorption of Analgosedative Drugs in New Extracorporeal Membrane Oxygenation Circuits
  125. Correction: Catch–up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence
  126. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients
  127. Tramadol, breast feeding and safety in the newborn
  128. Drug evaluation studies in neonates: how to overcome the current limitations
  129. Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction
  130. Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term
  131. Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population
  132. Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree
  133. Developmental Pharmacokinetics in Neonates: Maturational Changes and Beyond
  134. Therapeutic Drug Monitoring in Neonates: What Makes them Unique?
  135. A Human Proximal Tubular Epithelial Cell Model to Explore a Knowledge Gap on Neonatal Drug Disposition
  136. Editorial: Neonatal Clinical Pharmacology: A Rapidly Maturing Discipline
  137. Drug metabolism in early infancy: opioids as an illustration
  138. Severity of asphyxia is a covariate of phenobarbital clearance in newborns undergoing hypothermia
  139. Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit
  140. Current and future antenatal management of isolated congenital diaphragmatic hernia
  141. Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range
  142. Analysis of renal blood flow and renal volume in normal fetuses and in fetuses with a solitary functioning kidney
  143. Biomarkers of propofol metabolism in neonates: the quest beyond ontogeny
  144. Better medicines for neonates: Improving medicine development, testing, and prescribing
  145. Evidence-based drug treatment for special patient populations through model-based approaches
  146. Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology
  147. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia
  148. Newborn genome-wide DNA methylation in association with pregnancy anxiety reveals a potential role for GABBR1
  149. Enrollment of Neonates in More Than One Clinical Trial
  150. Perinatal and neonatal use of paracetamol for pain relief
  151. Sleep related breathing disorders and indications for polysomnography in preterm infants
  152. Pre- and Postnatal Development of the Eye: A Species Comparison
  153. O-5 Amikacin disposition and dosing recommendations in neonates with perinatal asphyxia treated with therapeutic hypothermia (amicool study)
  154. O-13 Factors impacting unbound vancomycin concentrations in neonates and young infants
  155. Clinical outcome at 1 year of age for congenital diaphragmatic hernia in the era of fetal intervention
  156. Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population
  157. N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity
  158. Clinically relevant discordances identified after tertiary reassessment of fetuses with isolated congenital diaphragmatic hernia
  159. Continuous Intravenous Acetaminophen for Analgesia: First, Back to the Drawing Table?
  160. Risk factors for spontaneous localized intestinal perforation in the preterm infant
  161. Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies
  162. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group
  163. Exposure to acetaminophen and all its metabolites upon 10, 15, and 20 mg/kg intravenous acetaminophen in very-preterm infants
  164. Antibiotic Dosing in Pediatric Critically Ill Patients
  165. Meet Our Editorial Board Member
  166. Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence
  167. What is the dose of intravenous paracetamol for pain relief in neonates?
  168. Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics
  169. Fetal and neonatal rats paracetamol dosage and the perinatal human setting: Lost in translation?
  170. Simplified Thresholds for Pediatric (Pre)hypertension
  171. Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype
  172. The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population
  173. Catch–up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence
  174. Does Extremely Low Birth Weight Predispose to Low-Renin Hypertension?
  175. Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development
  176. Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism
  177. Clinical Outcome for Congenital Diaphragmatic Hernia at the Age of 1 Year in the Era of Fetal Intervention
  178. Harmonized Use of Frequently Prescribed Medicines in Preterm Neonates: Mission Impossible?
  179. Relation Between EEG Activity and Brain Oxygenation in Preterm Neonates
  180. The Impact of Kidney Development on the Life Course: A Consensus Document for Action
  181. The role of population pharmacokinetic analysis in rational antibiotic therapy in neonates
  182. Drawbacks of Analgesics in Neonatal Age: How to Ensure Safe and Effective Use in Newborns
  183. Catch-Up Growth in Former Preterm Neonates: No Time to Waste
  184. Propofol Dose-Finding to Reach Optimal Effect for (Semi-)Elective Intubation in Neonates
  185. Adverse drug events in pediatric intensive care are common, but improvement strategies exist and are effective
  186. Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period
  187. Paracetamol and morphine for infant and neonatal pain; still a long way to go?
  188. A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey
  189. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates
  190. Acetaminophen to Prevent Symptomatic Patent Ductus Arteriosus: Another Drug Bites the Dust?
  191. Erratum to: A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetanide: Lessons to Help Improve Future Product Development in Neonates
  192. The amikacin research program: a stepwise approach to validate dosing regimens in neonates
  193. Intravenous paracetamol and intraocular pressure reduction: mannitol may also be involved
  194. [OP.1B.01] VITAMIN K DEPENDENT PROTECTION OF RENAL FUNCTION IN MULTI-ETHNIC POPULATION STUDIES
  195. [OP.1A.10] CONVENTIONAL AND AMBULATORY BLOOD PRESSURE AS PREDICTORS OF RETINAL ARTERIOLAR NARROWING
  196. Pharmacological sedation management in the paediatric intensive care unit
  197. A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetamide: Lessons to Help Improve Future Product Development in Neonates
  198. Esophageal Atresia: Future Directions for Research on the Digestive Tract
  199. Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing
  200. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants
  201. Eventos adversos a medicamentos em terapia intensiva pediátrica são comuns, mas estratégias de melhoria existem e são eficazes
  202. Can peak creatininemia be used as risk indicator for retinopathy of prematurity in ELBW infants?
  203. Retinal microvascular diameter, a hypertension-related trait, in ECG-gated vs. non-gated images analyzed by IVAN and SIVA
  204. Neonatal pain management: still in search for the Holy Grail
  205. Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use
  206. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling
  207. All medicines have side effects
  208. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro–In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound
  209. Clinical research in neonates and infants: Challenges and perspectives
  210. Score for Neonatal Acute Physiology-II Predicts Outcome in Congenital Diaphragmatic Hernia Patients*
  211. Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy
  212. Clinical pharmacokinetics of amoxicillin in neonates
  213. Substitution as a Strategy to Improve Excipient Exposure in Neonates: One Piece of the Puzzle
  214. Conventional Mechanical Ventilation Versus High-frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia
  215. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates
  216. Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia
  217. Urine of Preterm Neonates as a Novel Source of Kidney Progenitor Cells
  218. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period
  219. Bronchodilator and Antihyperkalemic Effects of Salbutamol (Albuterol) in Neonates and Young Infants
  220. Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies
  221. Evidence-Based Use of α-2 Agonists for Sedation in the PICU
  222. Possible effects of repeated exposure to ibuprofen and acetaminophen on the intestinal immune response in young infants
  223. Therapeutic drug monitoring in neonates
  224. Comment on: Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects
  225. Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care
  226. Treating Pain in Preterm Infants: Moving from Opioids to Acetaminophen
  227. Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits
  228. Creatinine Assays in Early Infancy: How to Aim for a Moving Target
  229. Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates
  230. Changes in Oxygenation Levels Precede Changes in Amplitude of the EEG in Premature Infants
  231. Standardized Postnatal Management of Infants with Congenital Diaphragmatic Hernia in Europe: The CDH EURO Consortium Consensus - 2015 Update
  232. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
  233. Clinical Pharmacology of Paracetamol in Neonates: A Review
  234. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach
  235. Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data
  236. Dosing Guidelines of Aminoglycosides in Neonates: A Balance Between Physiology and Feasibility
  237. Paracetamol pharmacokinetics and metabolism in young women
  238. Neonatal withdrawal syndrome: reaching epidemic proportions across the globe
  239. Variation in paediatric hospital antibiotic guidelines in Europe
  240. Factors Impacting Unbound Vancomycin Concentrations in Different Patient Populations
  241. Dysphagia in Children with Esophageal Atresia: Current Diagnostic Options
  242. Meet Our Editorial Board Member:
  243. Developmental pharmacology: A moving target
  244. Relevance of the blood-brain barrier on compartmental pharmacokinetics of paracetamol
  245. The Fate of Fat: Pre-Exposure Fat Losses during Nasogastric Tube Feeding in Preterm Newborns
  246. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice
  247. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
  248. Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation
  249. Neonatal drug therapy: The first frontier of therapeutics for children
  250. Erratum
  251. Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants
  252. Design and feasibility of “PREMATurity as predictor of children's Cardiovascular–renal Health” (PREMATCH): A pilot study
  253. Adverse drug reactions in neonates and infants: a population-tailored approach is needed
  254. Neonatal creatinemia trends as biomarker of subsequent cognitive outcome in extremely low birth weight neonates
  255. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age
  256. Neonatal medicines research: challenges and opportunities
  257. Editorial Board Member Gerald Lushington
  258. Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
  259. Question: Is breastfeeding useful in the management of neonatal abstinence syndrome?: Table 1
  260. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates
  261. Novel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact
  262. Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
  263. 63: Transplacental sildenafil rescues vascular and airway morphometry in the rabbit model of congenital diaphragmatic hernia
  264. 659: Can problems with airway reestablishment after fetoscopic tracheal occlusion be predicted?
  265. Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract
  266. Cognitive assessment of very low birth weight infants using the Dutch version of the PARCA-R parent questionnaire
  267. Current Therapeutic Research is Now Indexed on PubMed
  268. Prospective validation of neonatal vancomycin dosing regimens is urgently needed
  269. Tympanic, Infrared Skin, and Temporal Artery Scan Thermometers Compared with Rectal Measurement in Children: A Real-Life Assessment
  270. Prediction of Neonatal Respiratory Function and Pulmonary Hypertension in Fetuses with Isolated Congenital Diaphragmatic Hernia in the Fetal Endoscopic Tracleal Occlusion Era: A Single-Center Study
  271. Cystatin C in newborns: a promising renal biomarker in search for standardization and validation
  272. The addition of tramadol to a standard IV acetaminophen/morphine analgesia protocol in neonates: purposeful or just polypharmacy?
  273. Tramadol and O-Desmethyl Tramadol Clearance Maturation and Disposition in Humans: A Pooled Pharmacokinetic Study
  274. Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother WithKCNJ11-Related Neonatal Diabetes
  275. Covariates of intravenous paracetamol pharmacokinetics in adults
  276. Sedation in the Neonatal Intensive Care Unit: International Practice
  277. Corrigendum to “Investigating the influence of maternal cortisol and emotional state during pregnancy on the DNA methylation status of the glucocorticoid receptor gene (NR3C1) promoter region in cord blood” [J Psychiatr Res 47 880–91]
  278. Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome
  279. Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data
  280. Switch in FGFR3 and -4 Expression Profile During Human Renal Development May Account for Transient Hypercalcemia in Patients With Sotos Syndrome due to 5q35 Microdeletions
  281. Neonatal Abstinence Syndrome
  282. Tailored tools to improve pharmacotherapy in infants
  283. Commentary
  284. Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates
  285. Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration
  286. Determination of Racemic Ketorolac, Ketorolac Enantiomers and Their Metabolites in Human Plasma and Urine by LC–UV, Applied in Clinical Study During and After Pregnancy
  287. Paired measurement of urinary creatinine in neonates based on a Jaffe and an enzymatic IDMS-traceable assay
  288. Impaired endothelial function in adolescents with overweight or obesity measured by peripheral artery tonometry
  289. Cardiac assessment in fetuses with right‐sided congenital diaphragmatic hernia: case–control study
  290. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates
  291. Cefazolin plasma protein binding in different human populations: More than cefazolin–albumin interaction
  292. Intravenous paracetamol dosage in the neonate and small infant
  293. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults
  294. Neonatal Formulations and Additives
  295. Clinical Pharmacology in Neonates: Small Size, Huge Variability
  296. Enzymatic isotope dilution mass spectrometry (IDMS) traceable serum creatinine is preferable over Jaffe in neonates and young infants
  297. Estradiol and Weight Are Covariates of Paracetamol Clearance in Young Women
  298. Perinatal Pharmacology
  299. Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
  300. The Clinical Relevance of Pediatric Formulations
  301. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults
  302. Clinical pharmacology of carbapenems in neonates
  303. The interplay between drugs and the kidney in premature neonates
  304. Analgosedation in neonates: what we know and how we act
  305. European Study of Neonatal Exposure to Excipients: An update
  306. A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates
  307. Association between Retinal Neovascularization and Serial Weight Measurements in Murine and Human Newborns
  308. Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology
  309. Investigating the influence of maternal cortisol and emotional state during pregnancy on the DNA methylation status of the glucocorticoid receptor gene (NR3C1) promoter region in cord blood
  310. Predictors of neonatal morbidity in fetuses with severe isolated congenital diaphragmatic hernia undergoing fetoscopic tracheal occlusion
  311. Neonatal circulatory failure due to acute hypertensive crisis : clinical and echocardiographic clues : cardiovascular topics
  312. Neonatal clinical pharmacology
  313. Paracetamol to induce ductus arteriosus closure: is it valid?
  314. Impaired endothelial function in female adolescents with type 1 diabetes measured by peripheral artery tonometry
  315. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings
  316. Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum
  317. Perinatal pharmacology
  318. Pharmacological treatment of neonatal pain: In search of a new equipoise
  319. Misdiagnosis as asphyxiating thoracic dystrophy and CMV-associated haemophagocytic lymphohistiocytosis in Shwachman-Diamond syndrome
  320. Pediatric clinical pharmacology: an introduction to a series of educational papers
  321. Paracetamol to close the patent ductus arteriosus: From serendipity toward evidence based medicine
  322. Concerning the timing of antibiotic administration in women undergoing caesarean section: a systematic review and meta-analysis
  323. Clinical pharmacology of intravenous paracetamol in perinatal medicine
  324. Developmental pharmacokinetics of propylene glycol in preterm and term neonates
  325. Do old pharmacokinetic parameter estimates predict new data?
  326. Remifentanil in Neonates: A Promising Compound in Search of its Indications?
  327. The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus
  328. The paracetamol concentration-effect relation in neonates
  329. Urinary metabolites after intravenous propofol bolus in neonates
  330. Pharmacokinetics of intravenous ketorolac following caesarean delivery
  331. The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery
  332. The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates
  333. Creatinine-Based Vancomycin Dosing Regimens in Neonates: There Is More to Consider Than the Variation in Drug Assay
  334. Cefazolin plasma protein binding and its covariates in neonates
  335. Clinical pharmacokinetics of vancomycin in the neonate: a review
  336. Ophthalmological Findings in Congenital Cytomegalovirus Infection: When to Screen, When to Treat?
  337. The influence of maternal cortisol and emotional state during pregnancy on fetal intrauterine growth
  338. Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?
  339. Educational paper: Do we need neonatal clinical pharmacologists?
  340. Development and Validation of a Chromatographic and Electrophoretic Method for the Determination of Amikacin and Urea in Bronchial Epithelial Lining Fluid
  341. Pharmacokinetics of Aminoglycosides in the Newborn
  342. Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations
  343. Continuous glucose monitoring and retinopathy of prematurity
  344. Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery
  345. Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method
  346. Congenital heart defects in a novel recurrent 22q11.2 deletion harboring the genes CRKL and MAPK1
  347. Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance
  348. A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span
  349. Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation
  350. Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach
  351. Effective analgesia after cesarean delivery needs pharmacokinetic input
  352. Inotropic Support in the NICU: Ever More Compounds in Search of Guidance?
  353. Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development: A Clinician’s Request for a More Integrated Approach
  354. Short-Term Use of Parenteral Nutrition With a Lipid Emulsion Containing a Mixture of Soybean Oil, Olive Oil, Medium-Chain Triglycerides, and Fish Oil
  355. The Impact of Caesarean Delivery on Paracetamol and Ketorolac Pharmacokinetics: A Paired Analysis
  356. 405: Prediction of neonatal respiratory function in fetuses with isolated congenital diaphragmatic hernia (CDH) in the FETO era
  357. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology
  358. Pharmacogenetics and Perinatal Clinical Pharmacology: Tool or Toy?
  359. Propylene Glycol in Neonates: Never Prescribed, Frequently Administered, Hardly Evaluated
  360. Outcome of fetuses with congenital diaphragmatic hernia and associated intrafetal fluid effusions managed in the era of fetal surgery
  361. Educational paper
  362. The Clinical Pharmacology of Short Acting Analgo-Sedatives in Neonates
  363. Perinatal pharmacology: Applications for neonatal neurology
  364. Pharmacokinetics and pharmacodynamics of intravenous acetaminophen in neonates
  365. Creatinaemia in ELBW Neonates: Jaffe Colorimetry Versus Enzymatic Analysis
  366. Is Hyperbilirubinaemia a Clinical Useful Indicator of Reduced Drug Clearance Capacity in Neonates?
  367. Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations
  368. Propylene Glycol Pharmacokinetics and Renal Elimination Capacity: Preliminary Observations
  369. Results of Fetal Endoscopic Tracheal Occlusion for congenital diaphragmatic hernia and the set up of the randomized controlled TOTAL trial
  370. P.4.e.002 The effects of prenatal stress on the intrauterine growth of the fetus
  371. Creatinaemia at birth is equal to maternal creatinaemia at delivery:does this paradigm still hold?
  372. Quantification of Amikacin in Bronchial Epithelial Lining Fluid in Neonates
  373. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates
  374. Mechanism based medicine in infancy: complex interplay between developmental pharmacology and pharmacogenetics
  375. Analgosedation in neonates: do we still need additional tools after 30 years of clinical research?
  376. Maternal hyperoxygenation test in fetuses undergoing FETO for severe isolated congenital diaphragmatic hernia
  377. The pharmacokinetics of intravenous paracetamol in neonates: size matters most
  378. Determination of Propylene Glycol in Low Volume Plasma and Urine Samples of Neonates by LC with Photodiode Array Detection
  379. Does intravenous paracetamol administration affect body temperature in neonates?
  380. Propofol in (pre)term neonates: consider the extensive interindividual variability in clearance within the neonatal population
  381. Differences in Copy Number Variation between Discordant Monozygotic Twins as a Model for Exploring Chromosomal Mosaicism in Congenital Heart Defects
  382. Pregnancy During Nitisinone Treatment for Tyrosinaemia Type I: First Human Experience
  383. 1255 Maternal Betamethason Administration is An Indicator But Not An Independent Risk Factor for Raised 17-Hydroxyprogesterone at Neonatal Screening
  384. 144 Incidence, Risk Factors and Severity of Pulmonary Morbidity in Infants with Congenital Diaphragmatic Hernia Born in High-Volume Centres in Europe
  385. 462 Covariates of Nurses' Management of Pain in Children
  386. 463 Passive Distraction is the Only Determinant of Pain During Venous Blood Sampling in School Children in An Outpatient Clinic Setting
  387. 938 Until When Does Creatinaemia in Elbw Infants Still Reflects Maternal Renal Function?
  388. 1363 Empirical Mode Decomposition to Assess Coupling Between Infants Cry Signals and Pain Expression Quantified by a Pain Score
  389. 478 Haemodynamics Following Intravenous Paracetamol Administration in (PRE) Term Neonates
  390. 473 Prospective Evaluation of Propylene Glycol Tolerance in (PRE) Term Neonates: An Active Comparator Approach
  391. Prospective assessment of short-term propylene glycol tolerance in neonates
  392. Cross-sectional Study of Tracheomegaly in Children after Fetal Tracheal Occlusion for Severe Congenital Diaphragmatic Hernia
  393. Determinants of drug absorption in different ECMO circuits
  394. Gabapentin as part of multimodal analgesia in a newborn with epidermolysis bullosa
  395. The pharmacology of anaesthetics in the neonate
  396. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance
  397. Bladder catheter-induced obstructive bilateral hydroureteronephrosis in a newborn
  398. Haemodynamics of intravenous paracetamol in neonates
  399. Assessment of Pain Expression in Infant Cry Signals Using Empirical Mode Decomposition
  400. Array Comparative Genomic Hybridization as a Diagnostic Tool for Syndromic Heart Defects
  401. Pain management during eye examinations for retinopathy of prematurity: what about procedural adaptations to blunt the pain response?
  402. Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model
  403. Langerhans cell histiocytosis presenting as recurrent air leaks in young children
  404. The role of population PK–PD modelling in paediatric clinical research
  405. Renal Side Effects of Non-Steroidal Anti-Inflammatory Drugs in Neonates
  406. Amniotic fluid markers of fetal cardiac dysfunction in twin-to-twin transfusion syndrome
  407. Cerebral and Systemic Hemodynamic Effects of Intravenous Bolus Administration of Propofol in Neonates
  408. Decoupling between fundamental frequency and energy envelope of neonate cries
  409. Standardized Postnatal Management of Infants with Congenital Diaphragmatic Hernia in Europe: The CDH EURO Consortium Consensus
  410. Perinatal Pharmacology
  411. Aminoglycoside pharmacokinetics in neonates: the need to search for covariates of variability in addition to case descriptions
  412. Clinical Pharmacology of Systemic Analgesics in Neonates
  413. Evidence and Patterns in Lung Response after Fetal Tracheal Occlusion: Clinical Controlled Study
  414. In Vivo Glucuronidation Activity of Drugs in Neonates: Extensive Interindividual Variability Despite Their Young Age
  415. Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?
  416. Cardiorespiratory Depression and Hyperglycemia after Unintentional Ingestion of Brimonidine in a Neonate
  417. Changing Perspectives on the Perinatal Management of Isolated Congenital Diaphragmatic Hernia in Europe
  418. Is Propofol the Perfect Hypnotic Agent for Procedural Sedation in Neonates?
  419. Fetal treatment for early dyshormonogenetic goiter
  420. Intravenous neonatal paracetamol dosing: the magic of 10 days
  421. Tramadol withdrawal in a neonate: only one of the clinical presentations to be anticipated…
  422. Clinical practice: analgesia in neonates
  423. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy
  424. Cefazolin plasma protein binding saturability during pregnancy
  425. Prenatal prediction of neonatal morbidity in survivors with congenital diaphragmatic hernia: a multicenter study
  426. The impact of ibuprofen or indomethacin on renal drug clearance in neonates
  427. The interindividual variability in metabolism of the analgesic tramadol in neonates is independent of their disease state characteristics
  428. Covariates of Amikacin Clearance in Neonates: The Impact of Postnatal Age on Predictability
  429. Urinary propofol metabolites in early life after single intravenous bolus
  430. Procedural sedation of neonates with chloral hydrate: a sedation procedure does not end at the end of the acquisition of the images
  431. How to use drugs for pain management: from pharmacokinetics to pharmacogenomics
  432. Prenatal prediction of survival in isolated diaphragmatic hernia using observed to expected total fetal lung volume determined by magnetic resonance imaging based on either gestational age or fetal body volume
  433. Amniotic fluid disposition of cefazolin during pregnancy
  434. Postmenstrual Age and CYP2D6 Polymorphisms Determine Tramadol O-demethylation in Critically Ill Neonates and Infants
  435. Neonatal transient respiratory depression after maternal urapidil infusion for hypertension
  436. Both postnatal and postmenstrual age contribute to the interindividual variability in tramadol glucuronidation in neonates
  437. Determination of amikacin in cerebrospinal fluid by high-performance liquid chromatography with pulsed electrochemical detection
  438. Hepatic tolerance of repeated intravenous paracetamol administration in neonates
  439. Developmental pharmacokinetics in neonates
  440. Covariates of tramadol disposition in the first months of life
  441. Gastric emptying in healthy newborns fed an intact protein formula, a partially and an extensively hydrolysed formula
  442. Cerebrospinal Fluid Compartmental Pharmacokinetics of Amikacin in Neonates
  443. DEVELOPMENTAL PHARMACOLOGY: NEONATES ARE NOT JUST SMALL ADULTS…
  444. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates
  445. 555: Prenatal prediction of survival in isolated diaphragmatic hernia with observed over expected total fetal lung volume determined by magnetic resonance imaging based either on fetal body volume or gestational age
  446. 558: Short term neonatal morbidity in severe left-sided congenital diaphragmatic hernia treated by tracheal occlusion before 30 weeks
  447. Shouldn't we reconsider procedural techniques to prevent neonatal pain?
  448. Maturational pharmacokinetics of single intravenous bolus of propofol
  449. Not all intravenous paracetamol formulations are created equal?
  450. Predictability of vancomycin pharmacokinetics in neonates
  451. Influence of duration of parenteral nutrition on retinopathy of prematurity
  452. Renal Drug Clearance in Preterm Neonates: Relation to Prenatal Growth
  453. Cardiorespiratory events recorded on home monitors: the effect of prematurity on later serious events
  454. Determinants of Drug Metabolism in Early Neonatal Life
  455. Omkeerbare ACEI-foetopathie na intra-uteriene blootstelling aan lisinopril tijdens de zwangerschap
  456. Observed to expected lung area to head circumference ratio in the prediction of survival in fetuses with isolated diaphragmatic hernia
  457. Urinary metabolites to assess in vivo ontogeny of hepatic drug metabolism in early neonatal life
  458. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
  459. Developmental pharmacokinetics of opioids in neonates
  460. Variation in management during and after retinal surgery for retinopathy of prematurity
  461. Reducing inter-individual variability in amikacin clearance in preterm neonates
  462. Lung-to-head ratio and liver position to predict neonatal morbidity in fetuses with isolated congenital diaphragmatic hernia: A multicenter study
  463. Prospective assessment of systemic side effects of topical ophthalmic drug administration for screening for retinopathy of prematurity
  464. Prospective assessment of systemic side effects of topical ophthalmic drug administration for screening for retinopathy of prematurity
  465. Interindividual variability of aminoglycoside pharmacokinetics in preterm neonates at birth
  466. Circulatory effects of antenatal betamethasone therapy in low birthweight infants
  467. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates
  468. Maturational changes in the in vivo activity of CYP3A4 in the first months of life
  469. Population clinical pharmacology of children: general principles
  470. Population clinical pharmacology of children: modelling covariate effects
  471. Levetiracetam Pharmacokinetics in Neonates at Birth
  472. Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants
  473. Comments on “Shift from Biliary to Urinary Elimination of Acetaminophen-Glucuronide in Acetaminophen-Pretreated Rats”: TABLE 1
  474. Contribution of Glucuronidation to Tramadol Disposition in Early Neonatal Life
  475. Impact of ibuprofen administration on renal drug clearance in the first weeks of life
  476. Limited predictability of amikacin clearance in extreme premature neonates at birth
  477. O-demethylation of tramadol in the first months of life
  478. Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates
  479. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P -450 2D6 activity
  480. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis1
  481. Pharmacodynamics of chloral hydrate in former preterm infants
  482. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age
  483. Tramadol concentrations in blood and in cerebrospinal fluid in a neonate
  484. Ibuprofen and cerebral oxygenation and circulation
  485. Variability in pain expression characteristics in former preterm infants
  486. Retinopathie bij de prematuur: trends in klinische bevindingen en toekomstperspectieven
  487. Association of patent ductus arteriosus and severe hypothyroidism in term newborns: coincidence or causal?
  488. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial
  489. The EPIBEL Study: Outcomes to Discharge From Hospital for Extremely Preterm Infants in Belgium
  490. 6 Impact of Administration of Analgesics During Neonatal Stay on Pain Expression Following Neonatal Stay in Former Preterm Infants
  491. 7 Ontogeny of Udp-Glucuronosyltransferase Activity During Repeated Administration of Propacetamol in Neonates
  492. Characteristics of respiratory syncytial virus-related apnoea in three infants
  493. Characteristics of respiratory syncytial virus-related apnoea in three infants
  494. Continuous infusion of medications in very low birth weight infants
  495. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates
  496. The use of methohexital during chest tube removal in neonates
  497. Congenital Diaphragmatic Hernia and Situs Inversus Totalis
  498. Correction of pseudophakic anisometropia in a patient with pseudoexfoliation using an implantable contact lens
  499. Threshold retinopathy at threshold of viability: the EpiBel study
  500. Dopamine is an indicator but not an independent risk factor for grade 3 retinopathy of prematurity in extreme low birthweight infants
  501. Methemoglobinemia and hemolysis after enteral administration of methylene blue in a preterm infant: relevance for pediatric surgeons
  502. Effects of Co-Administration of Ibuprofen-Lysine on the Pharmacokinetics of Amikacin in Preterm Infants during the First Days of Life
  503. Association of patent ductus arteriosus and severe hypothyroidism in term newborns: coincidence or causal?
  504. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age
  505. Retinopathy of Prematurity: Any Difference in Risk Factors between a High and Low Risk Population?
  506. Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a former preterm infant
  507. Cryotherapy for Threshold Retinopathy: Perioperative Management in a Single Center
  508. Pseudo-Bartter syndrome in a neonate on prostaglandin infusion
  509. Dopamine and Indomethacin: Independent Risk Factors for Threshold Retinopathy of Prematurity?
  510. Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed
  511. Structural and Functional Outcome in Infants Treated With Cryotherapy for Threshold Retinopathy Between 1989 and 1999
  512. Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity
  513. Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity
  514. Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection
  515. Neonatal transthoracic puncture in a case of congenital cystic adenomatoid malformation of the lung
  516. The use of methohexital during neonatal cardioversion
  517. About the rationale of the insertion of a Heimlich valve in the thoracostomy circuit in newborn infants and small children
  518. Symptomatic unilateral dolicho-ectasia of the intracranial arteries in a child
  519. Developmental Pharmacology